Benzocaine on MedWatch
This article was originally published in The Tan Sheet
Executive Summary
Consumers and healthcare professionals should be aware of possible adverse events, particularly methemoglobinemia, related to benzocaine sprays, FDA states in a Public Health Advisory posted Feb. 13 on MedWatch. The sprays are used in certain minor medical procedures to locally numb the mouth and throat and some methemoglobinemia events have been due to improper dosing, the agency explains. "FDA is aware of the reported adverse events and is reviewing all available safety data, but at this time is not planning action to remove the drugs from the market," the agency states. The advisory only applies to benzocaine sprays for the mouth and throat and excludes exterior topical benzocaine sprays, FDA clarifies...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.